Immature and new proteins need to be properly folded in the endoplasmic reticulum (ER) and acquire high complex structure to become functional proteins. Proteins that help the folding are called chaperons. Calnexin, one of them, was elucidated to be related to the recognition and storage of misfolded proteins and incomplete proteins in the ER. A splicing isoform of calnexin (calnexin ?185-520) that was discovered recently has different characteristics from calnexin that it does not have transmembrane domains and repeated domains related to the lectin activity and the calcium dependent activity. A genetic disease associated with calnexin is cystic fibrosis (CF). This disease has mutations of chloride channel (CFTR) that cause abnormal folding and as the result, calnexin holds the mutant CFTRs in the ER. It causes a variety of fatal symptoms. It is also reported that there is a possibility that calnexin ?185-520 prevents the interaction with calnexin. It is expected to become a new treatment for CF. This antibody is a monoclonal antibody that does not react with calnexin and recognizes only calnexin ?185-520. It can be used for Western blotting.
| Product Specifications |
| Application |
WB |
| Reactivity |
Human |
| Clonality |
Monoclonal (Clone No.: Anti Calnexin mAb 2E9) |
| Host |
Mouse |
